Search Results

655 results

  1. CORESTA Congress, Online, 2020, Smoke Science/Product Technology Groups, ST 11

    Extractable and leachable testing of electronic nicotine delivery systems

    MORLEY N.; McGUIGAN S.; THOMAS J.; FEILDEN A.
    Hall Analytical Laboratories Ltd, Manchester, U.K.
    Many electronic nicotine delivery systems (ENDS) contain multiple components which are known to contain substances which have the potential to migrate from the components and potentially be exposed to the user. Thus, the assessment of extractables...
  2. CORESTA Congress, Online, 2020, Smoke Science/Product Technology Groups, ST 14

    In vitro assessment of acute respiratory toxicity

    SHARMA M.(1); STUCKI A.(1); VERSTRAELEN S.(2); FRIJNS E.(2); MAES F.(2); CLIPPINGER A.J.(1)
    (1) PETA International Science Consortium Ltd., Society Building, London, U.K.; (2) VITO, Flemish Institute for Technological Research, Mol, Belgium
    Efficient and effective assessment of inhaled substances using human-relevant approaches is important for product development and risk management. The aim of this project is to assess acute inhalation toxicity of chemicals using an in vitro system,...
  3. CORESTA Congress, Online, 2020, Smoke Science/Product Technology Groups, STPOST 02

    Analysis of highly volatile flavouring compounds in cigarettes smoke

    PINTO M.I.; PORTER R.; GHELLI J.; GOSS C.; THOMPSON N.; DALTON D.; WRIGHT C.
    British American Tobacco, R&D Centre, Southampton, U.K.
    A method for the analysis of highly volatile flavouring compounds in cigarette smoke is proposed. The extraction and concentration of these compounds is challenging because of the complexity of the smoke matrix, and the high vapour pressure and low...
  4. CORESTA Congress, Online, 2020, Smoke Science/Product Technology Groups, STPOST 15

    The comparative analysis of cytokine production by a human 3D airway tissue model following exposure to traditional cigarette smoke, tobacco-heated product and e-cigarette aerosol

    BEDFORD R.(1); ROTHWELL E.(1); MARTIN S.(1); O’HANLON C.(1); McCUNE A.(2); HOLLINGS M.(1)
    (1) Genetic Toxicology, Covance Laboratories Ltd, Harrogate, North Yorkshire, U.K.; (2) Immunology and Immunotoxicology, Covance Laboratories Ltd, Harrogate, North Yorkshire, U.K.
    The battery of regulatory assays currently used to assess the toxicity of aerosol exposure are limited in their ability to identify changes at the cellular and molecular level. This has prompted a shift towards a more holistic systems biology...
  5. CROM Symposium, Online, 2020, CROM 01

    A consortium approach for consumer-reported outcome measures for assessing tobacco and nicotine-containing products

    ACQUADRO C.(1); AFOLALU E.F.(2); BLACK R.A.(3); CAHOURS X.(4); CHREA C.(2); CLERC E.(2); CURTIN G.(5); EVANS S.(6); GILES L.(7); MacCAFFREY S.(3); PARK H.(8); PRASAD K.(9); SARKAR M.(10); SHIFFMAN S.(11); WEI Lay(10)
    (1) ICON PLC, Lyon, France; (2) Philip Morris Products SA, Switzerland; (3) JUUL Labs, Inc., USA; (4) Imperial Brands, France; (5) RAI Services Company, USA; (6) Turning Point Brands, USA; (7) JT International SA, Switzerland; (8) KT&G Research Institute, Republic of Korea; (9) British American Tobacco, U.K.; (10) Altria Client Services, USA; (11) Pinney Associates, USA
    The continuum of risk of tobacco products is generally accepted among public health authorities, where combustible products like cigarettes are the most risky and noncombustible products are at the lower end of the continuum. Adult smokers (AS)...
  6. CROM Symposium, Online, 2020, CROM 03

    Use of qualitative research to ensure we measure what matters to users of tobacco and/or nicotine products

    AFOLALU E.F.(1); CLERC E.(1); ABETZ-WEBB L.(2); CHREA C.(1)
    (1) Philip Morris Products SA, Neuchatel, Switzerland; (2) Patient-Centered Outcomes Assessments, Ltd, Cheshire, UK
    Cigarette smoking has a profound impact not on only physiological health but also perceived health and quality of life. There is currently a public health focus on cigarette smokers who switch to alternative smoke-free tobacco and nicotine-containing...
  7. CROM Symposium, Online, 2020, CROM 05

    Establishing traceability of self-reported dependence measurement through the use of crosswalks

    SALZBERGER T.(1); CANO S.(2); ABETZ-WEBB L.(3); AFOLALU E.F.(4); CHREA C.(4); WEITKUNAT R.(4); ROSE J.(6)
    (1) WU Wien (University of Economics and Business), Institute for Statistics and Mathematics, Austria; (2) Modus Outcomes, UK; (3) Patient-Centered Outcomes Assessments, UK; (4) PMI R&D, Philip Morris Products S.A., Switzerland; (6) Rose Research Center, LLC, USA
    Measurement in the social sciences has been characterized by deficient justification and underdeveloped conceptual theories. Instruments supposed to measure the same measurand typically do not provide comparable measurements. From the perspective of...
  8. CORESTA Meeting, Agronomy/Phytopathology, 2019, Victoria Falls, AP Sustainability Forum

    Agro-Phyto Sustainability Forum

    WILDE L.(1); PRIBIC V.(2); EVANS W.(3); ROYO E.(4); BARGIACCHI E.(5); COLARD S.(6)
    (1) twentyfifty Ltd, Frome, U.K.; (2) JT International S.A., Geneva, Switzerland; (3) Imperial Tobacco Limited, Durban, South Africa; (4) Philip Morris International, Cape Town, South Africa; (5) Consortium INSTM, Firenze, Italy; (6) CORESTA, Paris, France
    In 2015, the United Nations published 17 sustainable development goals and their corresponding targets to be achieved by 2030. Like other sectors, the tobacco and alternative product sectors are likely to impact most of the...
  9. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, ST 09

    The ABOUT™ Toolbox: toward the development of consumer-reported outcome measures that matter

    CHREA C.(1); SPIES E.(1); AFOLALU E.(1); BACSO A.(1); CLERC E.(1); MAINY N.(1); BINGGELI P.(1); WEITKUNAT R.(1); ACQUADRO C.(2); SALZBERGER T.(3); CANO S.(4); ABETZ-WEBB L.(5); ROSE J.(6)
    (1) PMI R&D, Philip Morris Products S.A., Neuchatel, Switzerland; (2) Mapi, an ICON plc Company, Lyon, France; (3) University of Economics and Business, Vienna, Austria; (4) ScaleReport, Ltd, Stotfold, U.K.; (5) Patient-Centered Outcomes Assessments, Ltd, Macclesfield Cheshire, U.K.; (6) Rose Research Center, Raleigh, U.S.A.
    Tobacco harm reduction promotes the substitution of reduced-risk products (RRPs) for cigarettes by adult smokers who would otherwise continue to smoke, while preventing RRP initiation among non-users. To operationalize this public health strategy,...
  10. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, ST 10

    Development of the ABOUT™–Health & Functioning: results from the preparatory phase

    SPIES E.(1); BACSO A.(1); CHREA C.(1); ABETZ-WEBB L.(2); AFOLALU E.(1); CLERC E.(1); WEITKUNAT R.(1)
    (1) PMI R&D, Philip Morris Products S.A., Neuchatel, Switzerland; (2) Patient-Centered Outcomes Assessments, Ltd, Macclesfield Cheshire, U.K.
    Switching cigarette smokers to significantly less harmful tobacco or nicotine products, or reduced-risk products (RRPs), has been recognized as a valuable and promising approach to reduce smoking-related population harm. Measuring self-reported...